Prognostic parameters in patients with advanced ovarian malignant tumors.
The role of a number of parameters was evaluated in 172 patients with advanced ovarian tumors. The clinical stage appears to be one of the most important of these parameters. Thus 3 years survival of patients in stage II was 40% whereas of those in stage IV only 5%. Granulosa cell tumors and mucinous cystadenocarcinomas presented the best prognosis while patients with undifferentiated and endometrioid carcinomas had a shorter survival. Patients with well differentiated tumors had a 3 year survival of 28% and those with poorly differentiated neoplasms 10%. Women under the age 50 showed a better prognosis than those over 50. The 3 year survival rate with residual tumors measuring less than 2 cm in diameter was 55% and that with residual tumors of more than 2 cm 18%. These parameters should therefore be carefully considered when therapy is being planned and when results of various therapeutic procedures are being compared.
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000401:mortality / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology; D003536:Cystadenocarcinoma / Q000401:mortality / Q000473:pathology; D005260:Female; D006106:Granulosa Cell Tumor / Q000401:mortality / Q000473:pathology; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000473:pathology; D011379:Prognosis